| Tiffany Barkley, DO | |
|
4000 Cambridge St, Kansas City, KS 66160-4619 | |
| (913) 588-1227 | |
| (913) 588-6965 |
| Full Name | Tiffany Barkley |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 9 Years |
| Location | 4000 Cambridge St, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740675891 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| North Kansas City Hospital | North kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Heart disease is the number one killer in the world and India carries more than its share of this burden. Moreover, the problem is set to rise: it is predicted that by 2010 India's population will suffer approximately 60% of the world's heart disease.
The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.
To combat the rise of drug-resistant bacteria, researchers are examining how one superbug adapts to fight an antibiotic of last resort, hoping to find clues that can prolong the drug's effectiveness.
› Verified 3 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Heart disease is the number one killer in the world and India carries more than its share of this burden. Moreover, the problem is set to rise: it is predicted that by 2010 India's population will suffer approximately 60% of the world's heart disease.
The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.
To combat the rise of drug-resistant bacteria, researchers are examining how one superbug adapts to fight an antibiotic of last resort, hoping to find clues that can prolong the drug's effectiveness.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tiffany Barkley, DO 3901 Rainbow Blvd Neurology Department, Kansas City, KS 66160-1104 Ph: (913) 588-1227 | Tiffany Barkley, DO 4000 Cambridge St, Kansas City, KS 66160-4619 Ph: (913) 588-1227 |
News Archive
Heart disease is the number one killer in the world and India carries more than its share of this burden. Moreover, the problem is set to rise: it is predicted that by 2010 India's population will suffer approximately 60% of the world's heart disease.
The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.
To combat the rise of drug-resistant bacteria, researchers are examining how one superbug adapts to fight an antibiotic of last resort, hoping to find clues that can prolong the drug's effectiveness.
› Verified 3 days ago
Joan M. T. Collison, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd # Ms 4015, Kansas City, KS 66160 Phone: 913-588-1300 Fax: 913-588-1310 | |
Dr. Andrea Lee, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3599 Rainbow Blvd, Kansas City, KS 66103 Phone: 913-588-6970 | |
James S Appelbaum, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 8919 Parallel Pkwy, Suite 440, Kansas City, KS 66112 Phone: 913-596-7286 Fax: 913-596-7248 | |
Dr. Robert T. Reynders, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Ms 1020, Kansas City, KS 66160 Phone: 913-588-3807 | |
Ahmad Abuzinadah, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Ms 2012, Kansas City, KS 66160 Phone: 913-588-6970 Fax: 913-588-6965 | |
Dr. Thomas Bryan Hall, Iii, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Department Of Psychiatry, Kansas City, KS 66160 Phone: 913-588-6400 | |
Debra Jean Kelsh, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-1304 Fax: 913-588-1310 |